Douglas Stephen A, Dhanak Dashyant, Johns Douglas G
Department of Vascular Biology, Cardiovascular and Urogenital Centre of Excellence for Drug Discovery, GlaxoSmithKline, PO Box 1539, 709 Swedeland Road, King of Prussia PA 19406-0939, USA.
Trends Pharmacol Sci. 2004 Feb;25(2):76-85. doi: 10.1016/j.tips.2003.12.005.
The identification of a human homolog of urotensin-II (U-II) and a novel, specific G-protein-coupled receptor by Ames et al. in 1999 changed the perception that the U-II isopeptide family was an esoteric collection of 'somatostatin-like neuropeptides' present only in the nervous systems of an eclectic array of aquatic invertebrates, fish and amphibians. In this article, we review recent developments in the pharmacology of human U-II, focusing on the actions of this peptide in the mammalian cardiorenal system. The putative role of U-II in the etiology of hypertension, heart failure, renal dysfunction and diabetes is discussed, as are novel U-II receptor antagonists.
1999年,艾姆斯等人鉴定出了urotensin-II(U-II)的人类同源物以及一种新型的特异性G蛋白偶联受体,这一发现改变了人们此前的认知,即U-II肽家族是仅存在于各种水生无脊椎动物、鱼类和两栖动物神经系统中的一类晦涩难懂的“生长抑素样神经肽”。在本文中,我们综述了人类U-II药理学的最新进展,重点关注该肽在哺乳动物心肾系统中的作用。文中讨论了U-II在高血压、心力衰竭、肾功能不全和糖尿病病因学中的假定作用,以及新型U-II受体拮抗剂。